Monoclonal and recombinant antibodies, 30 years after ..
In: Human Antibodies, Jg. 14 (2005-03-01), Heft 1/2, S. 33-55
academicJournal
Zugriff:
In 1975, the hybridoma technology provided, for the first time, an access to murine monoclonal antibodies. During the two following decades, their high potential, as laboratory tools, was rapidly exploited, but in vivo applications were still very limited. Nowadays, antibodies, omnipresent in both diagnostic and research domains, are largely invading the domain of therapy. A wide array of novel technologies, including phage display and transgenic mice, to isolate fully human antibodies and engineer these molecules, has been implemented. The natural propensity, of the antibody molecules, to metamorphosis makes them an ideal response to new applications and therapeutic challenges. The present review is a tentative update of the different antibody "formats" and a walk through the techniques recently applied to antibody engineering. In addition it also addresses some specific issues such as the development of expression systems suitable for large-scale production of recombinant antibodies. [ABSTRACT FROM AUTHOR]
Copyright of Human Antibodies is the property of IOS Press and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Titel: |
Monoclonal and recombinant antibodies, 30 years after ..
|
---|---|
Autor/in / Beteiligte Person: | Laffly, Emmanuelle ; Sodoyer, Regis |
Zeitschrift: | Human Antibodies, Jg. 14 (2005-03-01), Heft 1/2, S. 33-55 |
Veröffentlichung: | 2005 |
Medientyp: | academicJournal |
ISSN: | 1093-2607 (print) |
Schlagwort: |
|
Sonstiges: |
|